TABLE 1.
Sensitivity to α-HGA of clinical HIV-1 isolates
| Isolate | Resistance mutation(s)a | Clade | CPE in MT2b | EC50 (μM α-HGA)c |
|---|---|---|---|---|
| HI90-79 | RT: M230V; P: M36I, L63P, A71T, I93L | B | Neg | 24 |
| HI90-317 | RT: M41L, T215Y; P: M36I, L63P, A71T, I93L | B | ND | 20 |
| HI93-49 | RT:L74V, V106I; P: L63P | B | Neg | 15 |
| HI93-124 | RT: N67D, T69D, K70R, T215F, K219Q; P: L63P | B | Pos | 33 |
| HI94-18 | RT: M230S; P: no mutations | B | Neg | 16 |
| HI95-10 | RT: V179I; P: M36I, L63P | RT: A; P: CRF01-AE | Neg | 14 |
| HI96-88 | RT: M41L, E44A, D67N, T69D, L210W, T215Y; P: L63P | B | Neg | 24 |
| HI96-90 | RT: M41L, E44A, V118L, M184V, L210W, T215Y; P: L10I, L63P | B | Neg | 8.6 |
| HI97-59 | RT: M184V, L210W, T215Y; P: L10I, L63T | B | Neg | 4.2 |
| HI98-9 | RT: M41L, M184V, T215Y; P: L10I, L24I, L63P, V77I, V82T/S | B | Neg | 34 |
| HI98-80 | RT: M41L, D67N, M184V, T215F, K219Q; P: M36I | A | Neg | 5.5 |
| HI98-82 | RT: M184V; P: L10I, I47M, L63P, I93L | B | Neg | 33 |
| HI98-96 | RT: D67N, T69N, K70R, A98G, M184V, T215F, K219Q; P: L63P, G73T, D60E, L90M | B | Neg | 4.6 |
| HI98-100 | RT: M41L, A98G, M184V, L210W, T215Y; P: L10F, K20R, M36I, M46I, L63P, V82A | C | Neg | 16 |
| HI99-58 | RT: D67N, K70R, A98S, Y181C, K219Q; P: M36I, L63P, I93L | B | Neg | 7.6 |
a
The mutations depicted are those giving resistance to reverse transcriptase (RT) and protease (P); those indicated in boldface are primary.
b
A positive (Pos) cytopathic effect (CPE) in MT2 cells indicates syncytium formation and CXCR4 usage, whereas negative (Neg) CPE indicates CCR5 usage. ND, not done.
c
The geometric mean EC50 (μM α-HGA) for all of these isolates is 14 μM.